• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / AT7519 – CDK inhibitor2 / 20093 / 2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase...

2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study

25 November 2009/in 2009, AT7519 – CDK inhibitor, Products

2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2009-11-25 14:01:412016-11-25 14:09:472009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe Link to: Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe Link to: 2009 EORTC: Fragment Based Drug Discovery of HSP90 Inhibitor AT13387 Link to: 2009 EORTC: Fragment Based Drug Discovery of HSP90 Inhibitor AT13387 2009 EORTC: Fragment Based Drug Discovery of HSP90 Inhibitor AT13387
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.